Zhejiang ACEA Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2015-11-23
- Employees
- -
- Market Cap
- -
- Website
- https://www.aceapharma.com
A Bioequivalence Trial of Fasting Single Oral STI-1558 Capsule in Healthy Chinese Subjects
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06044233
- Locations
- 🇨🇳
Zhejiang Xiaoshan Hospital, Hangzhou, China
A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT05947344
- Locations
- 🇨🇳
the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
[14C] Study on Mass Balance and Biotransformation of STI-1558 in Healthy Chinese Adult Male Subjects
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Drug: [14C]STI-1558
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05754411
- Locations
- 🇨🇳
Beijing Gaobo Boren Hospital, Beijing, China
Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
- Target Recruit Count
- 1218
- Registration Number
- NCT05716425
- Locations
- 🇨🇳
Beijing Ditan Hospital, Capital Medical University, Beijing, China
🇨🇳Shenzhen Third People 's Hospital, Shenzhen, China
A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558
Phase 1
Completed
- Conditions
- COVID-19 Pneumonia
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT05685719
- Locations
- 🇨🇳
Zhejiang Xiaoshan Hospital, Hangzhou, Zhejiang, China
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Biological: STI-6129
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT05565807
- Locations
- 🇨🇳
The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Beijing Chao-Yang Hospital，Capital Medicine University, Beijing, Beijing, China
🇨🇳The first affiliated hospital ,Sun Yat-sen University, Guangzhou, Guangdong, China
Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT05523739
- Locations
- 🇨🇳
The Third People's Hospital Of Shenzhen, Shenzhen, Guangdong, China
© Copyright 2025. All Rights Reserved by MedPath